Circio Holding ASA (CRNA) - Total Liabilities
Based on the latest financial reports, Circio Holding ASA (CRNA) has total liabilities worth Nkr23.25 Million NOK (≈ $2.45 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Circio Holding ASA net asset momentum to track the company's year-over-year net asset growth rate.
Circio Holding ASA - Total Liabilities Trend (2020–2025)
This chart illustrates how Circio Holding ASA's total liabilities have evolved over time, based on quarterly financial data.
Circio Holding ASA Competitors by Total Liabilities
The table below lists competitors of Circio Holding ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Minsa S.A.B. de C.V
MX:MINSAB
|
Mexico | MX$2.20 Billion |
|
Imexpharm Corp
VN:IMP
|
Vietnam | ₫442.31 Billion |
|
Alpha Teknova Inc
NASDAQ:TKNO
|
USA | $33.73 Million |
|
MK Electron Co. Ltd
KQ:033160
|
Korea | ₩1.48 Trillion |
|
Pyrophyte Acquisition Corp. II
NYSE:PAII
|
USA | $9.56 Million |
|
Vendome Acquisition Corporation I Class A Ordinary Shares
NASDAQ:VNME
|
USA | $205.86 Million |
|
Bygg Partner i Dalarna Holding AB
ST:BYGGP
|
Sweden | Skr1.41 Billion |
|
Danal Co. Ltd
KQ:064260
|
Korea | ₩519.07 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Circio Holding ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Circio Holding ASA.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Circio Holding ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Circio Holding ASA (2020–2025)
The table below shows the annual total liabilities of Circio Holding ASA from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Nkr23.25 Million ≈ $2.45 Million |
-32.30% |
| 2024-12-31 | Nkr34.34 Million ≈ $3.61 Million |
-72.36% |
| 2023-12-31 | Nkr124.25 Million ≈ $13.07 Million |
+26.99% |
| 2022-12-31 | Nkr97.85 Million ≈ $10.30 Million |
-33.68% |
| 2021-12-31 | Nkr147.54 Million ≈ $15.53 Million |
-0.41% |
| 2020-12-31 | Nkr148.15 Million ≈ $15.59 Million |
-- |
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a … Read more